United Ubenimex Thalidomide Treatment Of Relapsed Or Refractory Multiple Myeloma Cancer

ObjectiveTo investigate the Ubenimex United thalidomide treatment of refractory and relapsed multiple myeloma and its application value.Methodsrelapsed or refractory myeloma patients were divided into 3 groups. Ubenimex thalidomide VAD group 13 cases, Ubenimex oral 30 mg fasting morning, starting dose of thalidomide 50 mg/d, a weekly increase of 50 mg, from 100-200 mg/d, vindesine 4 mg the first day of epirubicin 10 mg to the first four days of dexamethasone 20mg/d to the first four days; VAD thalidomide group,13 cases of thalidomide and VAD usage dosage Ibid; single VAD group with 13 cases, the use of ibid. ResultsUbenimex thalidomide group after treatment than before treatment the average 8.1 percent increase in hemoglobin concentration, percentage of myeloma cells decreased 3.9%, IgG dropped 59.1%, IgA decreased 75.1%; before and after treatment mparison, P values were 0.58,<0.01,0.037,0.014. Ubenimex thalidomide group and the other two groups after treatment compared IgG and IgA levels were significantly lower, P <0.05, there is statistical significance.ConclusionUbenimex thalidomide VAD program can effectively reduce the relapsed or refractory multiple myeloma patients with myeloma cell load, lower serum M protein content, and the total effective than thalidomide alone program and the United VAD single-program with VAD and light adverse reactions, patients with better tolerance for the clinical treatment of relapsed or refractory myeloma effect to provide a better program.